Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial – in other words, for now, that patient is cancer-free. This latest breakthrough – which could bode well for Chimeric shareholders, given the stock is currently suspended – comes on the back of a trial using a combination of ‘CORE-NK‘ and Vactosertib in advanced cancer patients. ‘CORE-NK’ takes its name from Natural Killer (NK) cells which “are part of our innate immune system,” according to the company’s website. A previous trial found more success combining it with Vactos…